NO964199D0 - Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon - Google Patents

Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon

Info

Publication number
NO964199D0
NO964199D0 NO964199A NO964199A NO964199D0 NO 964199 D0 NO964199 D0 NO 964199D0 NO 964199 A NO964199 A NO 964199A NO 964199 A NO964199 A NO 964199A NO 964199 D0 NO964199 D0 NO 964199D0
Authority
NO
Norway
Prior art keywords
interferon
treatment
type
autoimmune disease
oral tolerance
Prior art date
Application number
NO964199A
Other languages
English (en)
Other versions
NO964199L (no
Inventor
David A Hafler
Howard L Weiner
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO964199L publication Critical patent/NO964199L/no
Publication of NO964199D0 publication Critical patent/NO964199D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rehabilitation Therapy (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
NO964199A 1994-04-08 1996-10-03 Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon NO964199D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
PCT/US1995/004120 WO1995027499A1 (en) 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon

Publications (2)

Publication Number Publication Date
NO964199L NO964199L (no) 1996-10-03
NO964199D0 true NO964199D0 (no) 1996-10-03

Family

ID=22844605

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964199A NO964199D0 (no) 1994-04-08 1996-10-03 Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon

Country Status (9)

Country Link
EP (1) EP0752880A4 (no)
JP (1) JPH09511745A (no)
AU (1) AU686797B2 (no)
BR (1) BR9507451A (no)
CA (1) CA2185353A1 (no)
HU (1) HUT74900A (no)
IL (1) IL113303A0 (no)
NO (1) NO964199D0 (no)
WO (1) WO1995027499A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
CZ122697A3 (en) * 1994-10-25 1997-09-17 Immulogic Pharma Corp Preparations and methods of treating disseminated sclerosis
JP4878664B2 (ja) * 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な液体インターフェロン処方物
JP2001511187A (ja) * 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
ATE367823T1 (de) 2000-05-24 2007-08-15 Us Health E-selectin zur behandlung oder vorbeugung von schlaganfall
JPWO2004058295A1 (ja) * 2002-12-26 2006-04-27 第一アスビオファーマ株式会社 類天疱瘡治療剤
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
CA2757287C (en) * 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
JP6590330B2 (ja) * 2013-11-11 2019-10-16 キッコーマン株式会社 経口免疫寛容増強物質のスクリーニング方法および経口免疫寛容増強組成物
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2844889A (en) * 1988-01-22 1989-07-27 Collagen Corporation Method for suppressing the growth of normal and cancer cells
KR950700082A (ko) * 1992-02-28 1995-01-16 로버트 씨. 비숍 바이스탠더(bystander)에 의한 자가면역질환을 처치하는 방법

Also Published As

Publication number Publication date
WO1995027499A1 (en) 1995-10-19
EP0752880A4 (en) 2000-08-09
AU2277695A (en) 1995-10-30
EP0752880A1 (en) 1997-01-15
CA2185353A1 (en) 1995-10-19
BR9507451A (pt) 1997-08-05
AU686797B2 (en) 1998-02-12
IL113303A0 (en) 1995-07-31
JPH09511745A (ja) 1997-11-25
HU9602750D0 (en) 1996-11-28
NO964199L (no) 1996-10-03
HUT74900A (en) 1997-02-28

Similar Documents

Publication Publication Date Title
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
NO933240L (no) Anordning ved og fremstilling av tannbörste
IT9083334A0 (it) Procedimento per l'estrazione e la purificazione di dna genomico umano
GB9609932D0 (en) Use of IL-12 and IFN alpha for the treatment of infectious diseases
NO964199D0 (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller type I interferon
NO964200D0 (no) Behandling av autoimmun sykdom ved anvendelse av oral tolerisering og/eller Th2-forsterkende cytokiner
EP0833914A4 (en) BETA-11 HUMAN CHEMOKINE AND ALPHA-1 HUMAN CHEMOKINE
NO970582D0 (no) Fremgangsmåte og blandinger nyttige i protylakse og behandling av endotoksin-relaterte tilstander
BR9707613A (pt) Misturas isentas de derivados poliferólicos processo de pre paração de misturas i e ii medicamentos e utilização das misturas
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
EP0531365A4 (en) Diagnosis and treatment of viral hepatitis
IL133088A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
IL133089A0 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer
FI956313L (fi) Lejeeringin ja siitä tehtyjen tuotteiden metamorfinen käsittely
ZA9511021B (en) Plasma expanders and blood substitutes
ZA939756B (en) Monocional antibodies and anti-idiotypic antibodies to hepatitits c virus
PL322002A1 (en) Variants of human dnase i
NO981719D0 (no) Anvendelse av protein S-100b i medisiner og medisiner inneholdende protein S-100b
DE69634044D1 (de) Menschliches cyclin i und das dafuer kodierende gen
ITRM940210A0 (it) Procedimento per la purificazione di soluzioni di policarbunati e di poliestercarbonati
EP0731064A3 (de) Aufarbeitung und Verwendung der Rückstände der Direkten Synthese von Organochlor- u./o. Chlorsilanen
ZA958950B (en) Treatment of hla-dr associated immunodeficiency with gamma-interferon
GB9510284D0 (en) Newbrite glass and ceramic treatment
UA25336A (uk) Спосіб лікуваhhя виразкової хвороби шлуhка та дваhадцятипалої кишки

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application